ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

TargetBeta

S1PR1

sphingosine-1-phosphate receptor 1 · also edg-1, D1S3362, CD363, EDG1 · Sphingosine 1-phosphate receptors

5 programs in company-led studies act on S1PR1, from 4 companies: 4 in phase 3, 1 approved with new studies. Each with where its target was read from.

Programs

Furthest phase first. A target read by rule is marked rule (5 of them); the others are the company’s own words or a reading by Claude, each quoted on the program’s page.

ProgramCompanyActs asFurthest phaseStudiesAlso acts onRead from
fingolimodruleNovartis–phase 4554 runningS1PR2, S1PR3, S1PR4, S1PR5NCIt
cenerimodruleViatris–phase 3145 running–ChEMBL
etrasimodrulePfizeragonistphase 3214 runningS1PR4, S1PR5ChEMBL
ponesimodruleJohnson & Johnson–phase 3162 running–NCIt
mocravimodruleNovartisagonistphase 351 runningMBTPS1ChEMBL

Also acted on by the same programs

Conditions their studies are in

Primary completions ahead

Each program’s next study to reach its primary completion, by the sponsor’s estimate.

What this can’t show

  • Only programs whose target has been read: most early programs are named only by a code and their companies do not say what they act on.
  • A target read by rule can be wrong; each program’s page quotes the words it was read from.
  • “Acts as” is read from the words its target was read from — agonist, antagonist, inhibitor, lowers it (an siRNA or antisense drug), degrader — and is a dash where they do not say, or say two things; an antibody that only “binds” says neither.
  • Programs in company-led studies on ClinicalTrials.gov with a study in the last two years; academic studies and other registries are not counted here.